Seminal citrate is superior to PSA for detecting clinically significant prostate cancer

Detalhes bibliográficos
Autor(a) principal: Gregório,Emerson Pereira
Data de Publicação: 2019
Outros Autores: Alexandrino,Antonio Paulo, Schuquel,Ivania Terezinha Albrecht, Costa,Willian Ferreira da, Rodrigues,Marco Aurelio de Freitas
Tipo de documento: Artigo
Idioma: eng
Título da fonte: International Braz J Urol (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382019000601113
Resumo: ABSTRACT Purpose: To establish whether the citrate concentration in the seminal fluid ([CITRATE]) measured by means of high-resolution nuclear magnetic resonance spectroscopy (1HNMRS) is superior to the serum prostate-specific antigen (PSA) concentration in detecting of clinically significant prostate cancer (csPCa) in men with persistently elevated PSA. Materials and Methods: The group of patients consisted of 31 consecutively seen men with histological diagnosis of clinically localized csPCa. The control group consisted of 28 men under long-term follow-up (mean of 8.7 ± 3.0 years) for benign prostate hyperplasia (BPH), with persistently elevated PSA (above 4 ng/mL) and several prostate biopsies negative for cancer (mean of 2.7 ± 1.3 biopsies per control). Samples of blood and seminal fluid (by masturbation) for measurement of PSA and citrate concentration, respectively, were collected from patients and controls. Citrate concentration in the seminal fluid ([CITRATE]) was determined by means of 1HNMRS. The capacities of PSA and [CITRATE] to predict csPCa were compared by means of univariate analysis and receiver operating characteristic (ROC) curves. Results: Median [CITRATE] was significantly lower among patients with csPCa compared to controls (3.93 mM/l vs. 15.53 mM/l). There was no significant difference in mean PSA between patients and controls (9.42 ng/mL vs. 8.57 ng/mL). The accuracy of [CITRATE] for detecting csPCa was significantly superior compared to PSA (74.8% vs. 54.8%). Conclusion: Measurement of [CITRATE] by means of 1HNMRS is superior to PSA for early detection of csPCa in men with elevated PSA.
id SBU-1_03a2f56c3aa30c0a2e57f0f609ed983a
oai_identifier_str oai:scielo:S1677-55382019000601113
network_acronym_str SBU-1
network_name_str International Braz J Urol (Online)
repository_id_str
spelling Seminal citrate is superior to PSA for detecting clinically significant prostate cancerProstate-Specific AntigenProstate cancerfamilial [Supplementary Concept]CitratesABSTRACT Purpose: To establish whether the citrate concentration in the seminal fluid ([CITRATE]) measured by means of high-resolution nuclear magnetic resonance spectroscopy (1HNMRS) is superior to the serum prostate-specific antigen (PSA) concentration in detecting of clinically significant prostate cancer (csPCa) in men with persistently elevated PSA. Materials and Methods: The group of patients consisted of 31 consecutively seen men with histological diagnosis of clinically localized csPCa. The control group consisted of 28 men under long-term follow-up (mean of 8.7 ± 3.0 years) for benign prostate hyperplasia (BPH), with persistently elevated PSA (above 4 ng/mL) and several prostate biopsies negative for cancer (mean of 2.7 ± 1.3 biopsies per control). Samples of blood and seminal fluid (by masturbation) for measurement of PSA and citrate concentration, respectively, were collected from patients and controls. Citrate concentration in the seminal fluid ([CITRATE]) was determined by means of 1HNMRS. The capacities of PSA and [CITRATE] to predict csPCa were compared by means of univariate analysis and receiver operating characteristic (ROC) curves. Results: Median [CITRATE] was significantly lower among patients with csPCa compared to controls (3.93 mM/l vs. 15.53 mM/l). There was no significant difference in mean PSA between patients and controls (9.42 ng/mL vs. 8.57 ng/mL). The accuracy of [CITRATE] for detecting csPCa was significantly superior compared to PSA (74.8% vs. 54.8%). Conclusion: Measurement of [CITRATE] by means of 1HNMRS is superior to PSA for early detection of csPCa in men with elevated PSA.Sociedade Brasileira de Urologia2019-11-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382019000601113International braz j urol v.45 n.6 2019reponame:International Braz J Urol (Online)instname:Sociedade Brasileira de Urologia (SBU)instacron:SBU10.1590/s1677-5538.ibju.2018.0730info:eu-repo/semantics/openAccessGregório,Emerson PereiraAlexandrino,Antonio PauloSchuquel,Ivania Terezinha AlbrechtCosta,Willian Ferreira daRodrigues,Marco Aurelio de Freitaseng2019-12-12T00:00:00Zoai:scielo:S1677-55382019000601113Revistahttp://www.brazjurol.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||brazjurol@brazjurol.com.br1677-61191677-5538opendoar:2019-12-12T00:00International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)false
dc.title.none.fl_str_mv Seminal citrate is superior to PSA for detecting clinically significant prostate cancer
title Seminal citrate is superior to PSA for detecting clinically significant prostate cancer
spellingShingle Seminal citrate is superior to PSA for detecting clinically significant prostate cancer
Gregório,Emerson Pereira
Prostate-Specific Antigen
Prostate cancer
familial [Supplementary Concept]
Citrates
title_short Seminal citrate is superior to PSA for detecting clinically significant prostate cancer
title_full Seminal citrate is superior to PSA for detecting clinically significant prostate cancer
title_fullStr Seminal citrate is superior to PSA for detecting clinically significant prostate cancer
title_full_unstemmed Seminal citrate is superior to PSA for detecting clinically significant prostate cancer
title_sort Seminal citrate is superior to PSA for detecting clinically significant prostate cancer
author Gregório,Emerson Pereira
author_facet Gregório,Emerson Pereira
Alexandrino,Antonio Paulo
Schuquel,Ivania Terezinha Albrecht
Costa,Willian Ferreira da
Rodrigues,Marco Aurelio de Freitas
author_role author
author2 Alexandrino,Antonio Paulo
Schuquel,Ivania Terezinha Albrecht
Costa,Willian Ferreira da
Rodrigues,Marco Aurelio de Freitas
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Gregório,Emerson Pereira
Alexandrino,Antonio Paulo
Schuquel,Ivania Terezinha Albrecht
Costa,Willian Ferreira da
Rodrigues,Marco Aurelio de Freitas
dc.subject.por.fl_str_mv Prostate-Specific Antigen
Prostate cancer
familial [Supplementary Concept]
Citrates
topic Prostate-Specific Antigen
Prostate cancer
familial [Supplementary Concept]
Citrates
description ABSTRACT Purpose: To establish whether the citrate concentration in the seminal fluid ([CITRATE]) measured by means of high-resolution nuclear magnetic resonance spectroscopy (1HNMRS) is superior to the serum prostate-specific antigen (PSA) concentration in detecting of clinically significant prostate cancer (csPCa) in men with persistently elevated PSA. Materials and Methods: The group of patients consisted of 31 consecutively seen men with histological diagnosis of clinically localized csPCa. The control group consisted of 28 men under long-term follow-up (mean of 8.7 ± 3.0 years) for benign prostate hyperplasia (BPH), with persistently elevated PSA (above 4 ng/mL) and several prostate biopsies negative for cancer (mean of 2.7 ± 1.3 biopsies per control). Samples of blood and seminal fluid (by masturbation) for measurement of PSA and citrate concentration, respectively, were collected from patients and controls. Citrate concentration in the seminal fluid ([CITRATE]) was determined by means of 1HNMRS. The capacities of PSA and [CITRATE] to predict csPCa were compared by means of univariate analysis and receiver operating characteristic (ROC) curves. Results: Median [CITRATE] was significantly lower among patients with csPCa compared to controls (3.93 mM/l vs. 15.53 mM/l). There was no significant difference in mean PSA between patients and controls (9.42 ng/mL vs. 8.57 ng/mL). The accuracy of [CITRATE] for detecting csPCa was significantly superior compared to PSA (74.8% vs. 54.8%). Conclusion: Measurement of [CITRATE] by means of 1HNMRS is superior to PSA for early detection of csPCa in men with elevated PSA.
publishDate 2019
dc.date.none.fl_str_mv 2019-11-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382019000601113
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382019000601113
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/s1677-5538.ibju.2018.0730
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Urologia
publisher.none.fl_str_mv Sociedade Brasileira de Urologia
dc.source.none.fl_str_mv International braz j urol v.45 n.6 2019
reponame:International Braz J Urol (Online)
instname:Sociedade Brasileira de Urologia (SBU)
instacron:SBU
instname_str Sociedade Brasileira de Urologia (SBU)
instacron_str SBU
institution SBU
reponame_str International Braz J Urol (Online)
collection International Braz J Urol (Online)
repository.name.fl_str_mv International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)
repository.mail.fl_str_mv ||brazjurol@brazjurol.com.br
_version_ 1750318077205020672